Logo image of TENX

TENAX THERAPEUTICS INC (TENX) Stock Fundamental Analysis

NASDAQ:TENX - Nasdaq - US88032L6056 - Common Stock - Currency: USD

5.9  -0.05 (-0.84%)

After market: 5.93 +0.03 (+0.51%)

Fundamental Rating

3

Taking everything into account, TENX scores 3 out of 10 in our fundamental rating. TENX was compared to 558 industry peers in the Biotechnology industry. TENX has a great financial health rating, but its profitability evaluates not so good. TENX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TENX had negative earnings in the past year.
TENX had a negative operating cash flow in the past year.
TENX had negative earnings in each of the past 5 years.
TENX had a negative operating cash flow in each of the past 5 years.
TENX Yearly Net Income VS EBIT VS OCF VS FCFTENX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

TENX has a better Return On Assets (-21.61%) than 77.42% of its industry peers.
TENX has a better Return On Equity (-22.15%) than 83.51% of its industry peers.
Industry RankSector Rank
ROA -21.61%
ROE -22.15%
ROIC N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
TENX Yearly ROA, ROE, ROICTENX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

TENX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TENX Yearly Profit, Operating, Gross MarginsTENX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, TENX has more shares outstanding
Compared to 5 years ago, TENX has more shares outstanding
There is no outstanding debt for TENX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TENX Yearly Shares OutstandingTENX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
TENX Yearly Total Debt VS Total AssetsTENX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

TENX has an Altman-Z score of 1.66. This is a bad value and indicates that TENX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TENX (1.66) is better than 70.25% of its industry peers.
There is no outstanding debt for TENX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.66
ROIC/WACCN/A
WACCN/A
TENX Yearly LT Debt VS Equity VS FCFTENX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

TENX has a Current Ratio of 40.48. This indicates that TENX is financially healthy and has no problem in meeting its short term obligations.
TENX has a better Current ratio (40.48) than 98.92% of its industry peers.
A Quick Ratio of 40.48 indicates that TENX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 40.48, TENX belongs to the top of the industry, outperforming 98.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 40.48
Quick Ratio 40.48
TENX Yearly Current Assets VS Current LiabilitesTENX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

TENX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.64%, which is quite impressive.
EPS 1Y (TTM)90.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.50% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y79.36%
EPS Next 2Y33.61%
EPS Next 3Y21.83%
EPS Next 5Y16.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TENX Yearly Revenue VS EstimatesTENX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2027 2028 2029 2030 2031 2032 200M 400M 600M
TENX Yearly EPS VS EstimatesTENX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5K -10K -15K -20K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TENX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TENX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TENX Price Earnings VS Forward Price EarningsTENX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TENX Per share dataTENX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A more expensive valuation may be justified as TENX's earnings are expected to grow with 21.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.61%
EPS Next 3Y21.83%

More info and screens

0

5. Dividend

5.1 Amount

TENX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TENAX THERAPEUTICS INC

NASDAQ:TENX (7/16/2025, 2:46:50 PM)

After market: 5.93 +0.03 (+0.51%)

5.9

-0.05 (-0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners66.59%
Inst Owner Change0%
Ins Owners0.23%
Ins Owner Change0%
Market Cap24.48M
Analysts88
Price Target22.1 (274.58%)
Short Float %8.14%
Short Ratio14.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.12%
Min EPS beat(2)-41.99%
Max EPS beat(2)58.23%
EPS beat(4)3
Avg EPS beat(4)28.11%
Min EPS beat(4)-41.99%
Max EPS beat(4)86.6%
EPS beat(8)5
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)12.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.13%
EPS NY rev (1m)0%
EPS NY rev (3m)68.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.22
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-4
FCFYN/A
OCF(TTM)-4
OCFYN/A
SpS0
BVpS26.34
TBVpS26.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.61%
ROE -22.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-136.22%
ROA(5y)-220.51%
ROE(3y)-284.78%
ROE(5y)-368.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 40.48
Quick Ratio 40.48
Altman-Z 1.66
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.03%
EPS Next Y79.36%
EPS Next 2Y33.61%
EPS Next 3Y21.83%
EPS Next 5Y16.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-153.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.82%
OCF growth 3YN/A
OCF growth 5YN/A